India's drug-patent rules | The Economist

As pharmaceutical giants Novartis and Bayer challenge India's drug-patent rules, our correspondents discuss the potential implications for health care in the developing world

Subscribe NOW to The Economist: http://econ.st/1Fsu2Vj

Get more The Economist
Follow us: https://twitter.com/TheEconomist
Like us: https://www.facebook.com/TheEconomist
View photos: https://instagram.com/theeconomist/

The Economist videos give authoritative insight and opinion on international news, politics, business, finance, science, technology and the connections between them.